Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

Contact transmission of influenza virus between ferrets imposes a looser bottleneck than respiratory droplet transmission allowing propagation of antiviral resistance.

Frise R, Bradley K, van Doremalen N, Galiano M, Elderfield RA, Stilwell P, Ashcroft JW, Fernandez-Alonso M, Miah S, Lackenby A, Roberts KL, Donnelly CA, Barclay WS.

Sci Rep. 2016 Jul 19;6:29793. doi: 10.1038/srep29793.

2.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015.

Hurt AC, Besselaar TG, Daniels RS, Ermetal B, Fry A, Gubareva L, Huang W, Lackenby A, Lee RT, Lo J, Maurer-Stroh S, Nguyen HT, Pereyaslov D, Rebelo-de-Andrade H, Siqueira MM, Takashita E, Tashiro M, Tilmanis D, Wang D, Zhang W, Meijer A.

Antiviral Res. 2016 Aug;132:178-85. doi: 10.1016/j.antiviral.2016.06.001. Epub 2016 Jun 3.

3.

Late Ebola virus relapse causing meningoencephalitis: a case report.

Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, Gifford RJ, Hopkins S, Hughes J, Jabeen F, Johannessen I, Karageorgopoulos D, Lackenby A, Lester R, Liu RS, MacConnachie A, Mahungu T, Martin D, Marshall N, Mepham S, Orton R, Palmarini M, Patel M, Perry C, Peters SE, Porter D, Ritchie D, Ritchie ND, Seaton RA, Sreenu VB, Templeton K, Warren S, Wilkie GS, Zambon M, Gopal R, Thomson EC.

Lancet. 2016 Jul 30;388(10043):498-503. doi: 10.1016/S0140-6736(16)30386-5. Epub 2016 May 18.

4.

NB protein does not affect influenza B virus replication in vitro and is not required for replication in or transmission between ferrets.

Elderfield RA, Koutsakos M, Frise R, Bradley K, Ashcroft J, Miah S, Lackenby A, Barclay WS.

J Gen Virol. 2016 Mar;97(3):593-601. doi: 10.1099/jgv.0.000386. Epub 2015 Dec 24.

PMID:
26703440
5.

Self-sampling for community respiratory illness: a new tool for national virological surveillance.

Elliot AJ, Bermingham A, Charlett A, Lackenby A, Ellis J, Sadler C, Sebastianpillai P, Powers C, Foord D, Povey E, Evans B, Durnall H, Fleming DM, Brown D, Smith GE, Zambon M.

Euro Surveill. 2015 Mar 12;20(10):21058.

6.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.

Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H, Besselaar T, Fry A, Gregory V, Leang SK, Huang W, Lo J, Pereyaslov D, Siqueira MM, Wang D, Mak GC, Zhang W, Daniels RS, Hurt AC, Tashiro M.

Antiviral Res. 2015 May;117:27-38. doi: 10.1016/j.antiviral.2015.02.003. Epub 2015 Feb 23.

7.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.

Meijer A, Rebelo-de-Andrade H, Correia V, Besselaar T, Drager-Dayal R, Fry A, Gregory V, Gubareva L, Kageyama T, Lackenby A, Lo J, Odagiri T, Pereyaslov D, Siqueira MM, Takashita E, Tashiro M, Wang D, Wong S, Zhang W, Daniels RS, Hurt AC.

Antiviral Res. 2014 Oct;110:31-41. doi: 10.1016/j.antiviral.2014.07.001. Epub 2014 Jul 17.

8.

Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.

Perez-Sautu U, Pozo F, Cuesta I, Monzon S, Calderon A, Gonzalez M, Molinero M, Lopez-Miragaya I, Rey S, CaƱizares A, Rodriguez G, Gonzalez-Velasco C, Lackenby A, Casas I.

Euro Surveill. 2014 Jul 10;19(27):14-20.

9.

Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results.

Andrews N, McMenamin J, Durnall H, Ellis J, Lackenby A, Robertson C, von Wissmann B, Cottrell S, Smyth B, Moore C, Gunson R, Zambon M, Fleming D, Pebody R.

Euro Surveill. 2014 Jul 10;19(27):5-13.

10.

Risk factors for fatality in Panton-Valentine leukocidin-producing Staphylococcus aureus pneumonia cases, England, 2012-2013.

Dabrera G, Vickers A, Conaglen P, Evlampidou I, Lamagni T, Shetty N, Verlander N, Hill R, Gobin M, Campbell R, Zhao H, Johnson A, Ellis J, Lackenby A, Pichon B, Oliver I, Kearns A, Pebody R.

J Infect. 2014 Aug;69(2):196-9. doi: 10.1016/j.jinf.2014.03.007. Epub 2014 Mar 14. No abstract available.

PMID:
24637235
11.

A new laboratory-based surveillance system (Respiratory DataMart System) for influenza and other respiratory viruses in England: results and experience from 2009 to 2012.

Zhao H, Green H, Lackenby A, Donati M, Ellis J, Thompson C, Bermingham A, Field J, Sebastianpillai P, Zambon M, Watson J, Pebody R.

Euro Surveill. 2014 Jan 23;19(3). pii: 20680. Erratum in: Euro Surveill. 2014;19(20):pii/20808.

12.

Virological self-sampling to monitor influenza antiviral susceptibility in a community cohort.

Lackenby A, Elliot AJ, Powers C, Andrews N, Ellis J, Bermingham A, Thompson C, Galiano M, Large S, Durnall H, Fleming D, Smith G, Zambon M.

J Antimicrob Chemother. 2013 Oct;68(10):2324-31. doi: 10.1093/jac/dkt203. Epub 2013 Jun 12.

13.

Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013.

Health Protection Agency (HPA) UK Novel Coronavirus Investigation team.

Euro Surveill. 2013 Mar 14;18(11):20427.

14.

Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-confirmed influenza infection in primary care in the United Kingdom: mid-season analysis 2012/13.

McMenamin J, Andrews N, Robertson C, Fleming D, Durnall H, von Wissmann B, Ellis J, Lackenby A, Cottrell S, Smyth B, Zambon M, Moore C, Watson J, Pebody R.

Euro Surveill. 2013 Jan 31;18(5). pii: 20393.

15.

Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe.

Pozo F, Lina B, Andrade HR, Enouf V, Kossyvakis A, Broberg E, Daniels R, Lackenby A, Meijer A, Community Network of Reference Laboratories for Human Influenza in Europe.

J Clin Virol. 2013 May;57(1):5-12. doi: 10.1016/j.jcv.2013.01.009. Epub 2013 Jan 31.

PMID:
23375738
16.

Evaluation of influenza virus antiviral susceptibility testing in Europe: results from the first external quality assessment exercise.

Thompson CI, Lackenby A, Daniels RS, McCauley JW, Pereyaslov D, Broberg EK, Meijer A, Zambon MC.

J Clin Virol. 2013 Mar;56(3):212-8. doi: 10.1016/j.jcv.2012.11.005. Epub 2012 Nov 30.

PMID:
23201459
17.

Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.

Hurt AC, Chotpitayasunondh T, Cox NJ, Daniels R, Fry AM, Gubareva LV, Hayden FG, Hui DS, Hungnes O, Lackenby A, Lim W, Meijer A, Penn C, Tashiro M, Uyeki TM, Zambon M; WHO Consultation on Pandemic Influenza A (H1N1) 2009 Virus Resistance to Antivirals.

Lancet Infect Dis. 2012 Mar;12(3):240-8. doi: 10.1016/S1473-3099(11)70318-8. Epub 2011 Dec 18. Review.

PMID:
22186145
18.

Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010.

Calatayud L, Lackenby A, Reynolds A, McMenamin J, Phin NF, Zambon M, Pebody R.

Emerg Infect Dis. 2011 Oct;17(10):1807-15. doi: 10.3201/eid1710.110117.

19.

Clinical and socioeconomic impact of different types and subtypes of seasonal influenza viruses in children during influenza seasons 2007/2008 and 2008/2009.

Esposito S, Molteni CG, Daleno C, Valzano A, Fossali E, Da Dalt L, Cecinati V, Bruzzese E, Giacchino R, Giaquinto C, Lackenby A, Principi N.

BMC Infect Dis. 2011 Oct 12;11:271. doi: 10.1186/1471-2334-11-271.

20.

Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic.

Puzelli S, Facchini M, Di Martino A, Fabiani C, Lackenby A, Zambon M, Donatelli I.

Antiviral Res. 2011 Jun;90(3):205-12. doi: 10.1016/j.antiviral.2011.04.003. Epub 2011 Apr 14.

PMID:
21514326
Items per page

Supplemental Content

Loading ...
Write to the Help Desk